Loading...

CERO THERAPEUTICS HOLDINGS INC US FDA Inspections 8-K Filing

CR T

CERO THERAPEUTICS HOLDINGS INC

()

2025 8-K

Funding Agreement

Funding Agreement

Company Presentation

Nasdaq Delisting Notice

Investor Presentation Update

Stockholder Approvals

Equity Purchase Agreement

Delisting Notification

Fundraising Agreement

Investor Presentation Update

FDA Fast Track Designation

Nasdaq Listing Alert

Equity Offerings

Equity Offerings

Delisting due to Non-Compli...

Equity Offerings

Orphan Drug Designation

Voluntary Delisting

Equity Offerings

Reverse Stock Split

Initial Public Offerings

Rights Offerings

Private Placement

Nasdaq Compliance

Public Offering

Nasdaq Compliance Extension

Warrant Exercise

Cash Balance Update

CEO Appointment

Stock Purchase Agreement

Nasdaq Delisting Notice

Nasdaq Delisting Notice

FDA Submission Update

Financial Update

Management Changes

Stock Split Proposal

Meeting Postponed

Meeting Postponed

FDA Clinical Hold

Special Meeting with Stockh...

Amendment to include financ...

Purchase Agreement with Are...

Acquisition of CERo Therape...

Amendment to Business Combi...

Special Meeting and Stockho...

Amendment and PIPE Financing

Stockholder Meeting

Promissory Note Amendment

Update of Investor Presenta...

Stock Conversion

Merger Agreement

Charter Amendment Approval ...

External Links:

On June 17, 2025, Cero Therapeutics Holdings, Inc. announced that the FDA granted Orphan Drug Designation for their drug candidate CER-1236, aimed at treating acute myeloid leukemia.

AI Assistant

CERO THERAPEUTICS HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.